Solasia Pharma K.K. provided consolidated earnings forecasts for the fiscal year ending December 31, 2023. For the year, the company expected revenue to be in the range of JPY 1,000 million to JPY 1,800 million, operating loss to be in the range of JPY 1,150 million to JPY 350 million, loss to be in the range of JPY 1,150 million to JPY 350 million, loss attributable to owners of parent to be in the range of JPY 1,150 million to JPY 350 million and basic loss per share to be in the range of JPY 6.83 to JPY 2.08.